Latest Biomarker discovery Stories
NEW YORK, April 16, 2013 /PRNewswire/ -- Exosome Diagnostics, a developer of biofluid-based molecular diagnostic products for use in personalized medicine, today announced data demonstrating exosome technology performance in clinical applications which will be presented at the International Society for Extracellular Vesicles 2013 (ISEV 2013) annual meeting, April 16-20, in Boston. The ISEV meeting is the preeminent international conference in the rapidly growing field of exosome and...
NEW YORK, April 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C. The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by...
NORCROSS, Ga., Jan. 31, 2013 /PRNewswire/ -- RayBiotech, Inc. announced today that it has executed a master services agreement with Banner Sun Health Research Institute (BSHRI) of Sun City, Arizona. Under the terms of the agreement, RayBiotech will provide priority services for the biochemical analysis of disease markers in biological samples. A particular focus of the pact will be on the characterization of key biomarkers for the study of neurodegenerative disorders such as...
COLUMBIA, Md., Sept. 19, 2012 /PRNewswire/ -- BioFortis Inc., a leading software company in the clinical and translational research space, today introduced its Next Generation Biobanking software platform for biomarker-based clinical research. It will help pharmaceutical, government and academic research centers involved in biomarker-based clinical and translational studies to safely and effectively conduct externalized, science-driven collaborative studies. As biomarker-based...
BILLERICA, Mass., Sept. 4, 2012 /PRNewswire/ -- Aushon BioSystems today announced that Martin Verhoef has been appointed Chief Executive Officer. Mr. Verhoef has also been appointed to the Company's Board of Directors. Peter Honkanen, Founder and former Chief Executive Officer, will assume the Chief Operating Officer role and continue as a Board Director. (Logo: http://photos.prnewswire.com/prnh/20120621/NE25431LOGO) "We welcome Martin to Aushon and are especially excited about...
Great Point Partners, LLC today announced the sale of Caprion Proteomics, Inc., a Great Point Partners I portfolio company. GREENWICH, CT and MONTRÉAL, QUEBEC (PRWEB) July 20, 2012 Great Point Partners, LLC today announced the sale of Caprion Proteomics, Inc., a Great Point Partners I portfolio company. Caprion is a leading provider of proteomic services to the pharmaceutical industry that include: (i) biomarker discovery, (ii) biomarker validation, (iii) drug target discovery, (iv)...
PRINCETON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD), a leading provider of drug development services, announced today that it entered into a biomarker alliance and services agreement with Rules-Based Medicine, Inc. (RBM), a leading provider of multiplexed protein biomarker testing to the pharmaceutical industry. Subject to the terms of the agreement, Covance will use RBM as its exclusive third-party provider of multiplexed protein biomarker testing services, and RBM...
Biomedical Informatics Market Leader BioFortis wins another award for its Labmatrix(TM) platform being used by leading pharmaceutical and institutional clients worldwide for translational research, biomarker discovery, biobanking, and clinical research COLUMBIA, Md., March 5 /PRNewswire/ -- BioFortis, Inc., the leading provider of biomedical informatics solutions used by pharmaceutical and institutional clients, today announced it has won the 2009 Molecular Medicine Tri-Conference "Best...
CAMBRIDGE, Mass., Nov. 4 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics and molecular diagnostics, today announced that it has become a member of The Biomarker Consortium, a public/private research partnership managed by the Foundation for the National Institutes on Health (FNIH), and founded by the National Institutes of Health (NIH), the Food and Drug Administration (FDA)...
